ZNF385C Inhibitors
ZNF385C may contain inhibitors like Staurosporine and LY294002, which are known to broadly inhibit kinases, thereby disrupting protein function and signaling pathways that might intersect with ZNF385C's activity. U0126 and PD98059 target the MAPK/ERK pathway, a key regulatory route for cell proliferation and differentiation, which can alter the function of proteins that may be regulated by ZNF385C. SB203580 and SP600125 focus on the p38 MAPK and JNK pathways, respectively, with the potential to modify the activity of various proteins that could interact with or be regulated by ZNF385C.
Rapamycin and Wortmannin serve to inhibit the mTOR and PI3K/Akt pathways, respectively, leading to suppressed protein synthesis and affecting cellular growth and survival. These compounds can impact a range of proteins and cellular processes that may be related to ZNF385C function. Thalidomide, by modulating the degradation of transcription factors, can lead to broad changes in gene expression, possibly affecting proteins associated with ZNF385C. Nutlin-3, by stabilizing p53, can influence the cellular response to stress and DNA damage, affecting proteins in the p53 signaling pathway, which might be modulated by ZNF385C. Trichostatin A, as a histone deacetylase inhibitor, can change the expression levels of various proteins by altering chromatin structure, potentially impacting ZNF385C's role in gene regulation. Lastly, ICG-001 inhibits the Wnt/β-catenin pathway, influencing cellular processes and proteins related to this signaling cascade, which may include ZNF385C's regulatory activities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can disrupt multiple signaling pathways, impacting protein-protein interactions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can inhibit the PI3K/Akt signaling pathway, which may alter protein synthesis and cellular survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress protein synthesis by inhibiting mTORC1, potentially affecting proteins downstream in the pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that may alter inflammatory response and other p38 MAPK-regulated proteins. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that can lead to changes in Akt pathway signaling, which can affect numerous cellular proteins and processes. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates degradation of transcription factors, which can lead to changes in gene expression and protein production. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
MDM2 antagonist that can stabilize p53 protein, affecting proteins involved in the p53 signaling pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that can alter chromatin structure and gene expression, potentially affecting protein levels. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK inhibitor that may impact transcription factors and proteins regulated by the ERK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, possibly changing activity of proteins regulated by the JNK signaling pathway. | ||||||